Cost-utility analysis of interferon-free treatments for patients with early-stage genotype 1 hepatitis C virus in Brazil
Ferreira, Vinicius Lins; Leonart, Leticia Paula; Pedroso, Maria Lucia Alves; Pontarolo, Roberto.
Rev. Soc. Bras. Med. Trop;
53: e20190594, 2020. tab, graf
Artículo
en Inglés
| SES-SP, ColecionaSUS, LILACS | ID: biblio-1136866
Abstract INTRODUCTION We conducted a cost-utility analysis of available interferon-free treatments for patients with early-stage genotype 1 chronic hepatitis C based on a Brazilian public health system perspective. METHODS A Markov model was derived using a cohort of stage F0-F2 patients treated as recommended by the Brazilian national guidelines.
RESULTS:
Glecaprevir plus pibrentasvir was superior to all other treatments, followed by sofosbuvir plus velpatasvir. Sofosbuvir plus daclatasvir was identified as the least cost-effective option.CONCLUSIONS:
The above findings were confirmed via probabilistic sensitivity analysis and the tested scenarios.
Biblioteca responsable:
BR1.1
Texto completo